MDxHealth has signed a companion diagnostic agreement with German-based University Hospital of Bonn.
Under the agreement, University Hospital of Bonn will use MDxHealth’s epigenetic MGMT test (PredictMDxTM for Glioblastoma) to enroll brain cancer patients in a phase III CeTeG clinical study.
The multicenter, randomized study is designed to examine the addition of lomustine to the current therapy of temozolomide/radiotherapy in newly diagnosed MGMT methylated glioblastoma multiforme (GBM) patients.
MDxHealth’s MGMT test assesses the methylation status of the MGMT gene, which facilitates clinicians to take decision to treat patients requiring chemotherapy.